Valproic acid alleviates generalized hyperalgesia in mice with induced adenomyosis

Journal of Obstetrics and Gynaecology Research

Volumn 37, Issue 7, 2011, Pages 696-708

  Liu, Xishi ^a   Guo, Sun Wei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Adenomyosis; dysmenorrhea; hyperalgesia; infiltration; mouse; valproic acid

Indexed keywords

PROGESTERONE; TAMOXIFEN; VALPROIC ACID;

ADENOMYOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HYPERALGESIA; LOW DRUG DOSE; MOUSE; NEWBORN; NONHUMAN; TAIL FLICK TEST; THERMAL STIMULATION; TREATMENT RESPONSE;

ANALGESICS, NON-NARCOTIC; ANIMALS; ANIMALS, NEWBORN; ENDOMETRIOSIS; FEMALE; HYPERALGESIA; MICE; MICE, INBRED ICR; MYOMETRIUM; RANDOM ALLOCATION; TAMOXIFEN; TOCOLYTIC AGENTS; VALPROIC ACID;

EID: 80052751638     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2011.01655.x     Document Type: Article

References (49)

1. Bergeron C, Amant F, Ferenczy A. Pathology and physiopa-thology of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006; 20: 511-521.
2. Farquhar C, Brosens I. Medical and surgical management of adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006; 20: 603-616. (Pubitemid 44688625)
3. Matalliotakis IM, Kourtis AI, Panidis DK. Adenomyosis. Obstet Gynecol Clin North Am 2003; 30: 63-82, viii. (Pubitemid 36356713)
4. Guo SW. Epigenetics of endometriosis. Mol Hum Reprod 2009; 15: 587-607.
5. Liu X, Guo SW. A pilot study on the off-label use of valpr-oic acid to treat adenomyosis. Fertil Steril 2008; 89: 246-250.
6. Wu Y, Strawn E, Basir Z, Halverson G, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis. Epigenetics 2006; 1: 106-111.
7. Nie J, Liu XS, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent. Reprod Sci 2010; 17: 995-1005.
8. Liu X, Yuan L, Guo SW. Valproic acid as a therapy for adenomyosis: a comparative case series. Reprod Sci 2010; 17: 904-912.
9. Lu Y, Nie J, Liu X, Zheng Y, Guo SW. Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalge-sia in experimentally induced endometriosis in mice. Hum Reprod 2010; 25: 1014-1025.
10. Parrott E, Butterworth M, Green A, White IN, Greaves P. Adenomyosis: a result of disordered stromal differentiation. Am J Pathol 2001; 159: 623-630. (Pubitemid 32751092)
11. Green AR, Styles JA, Parrott EL et al. Neonatal tamoxifen treatment of mice leads to adenomyosis but not uterine cancer. Exp Toxicol Pathol 2005; 56: 255-263. (Pubitemid 40312750)
12. Mao X, Wang YD, Carter AV, Zhen X, Guo SW. The retarda-tion of myometrial infiltration, reduction of uterine contractility and alleviation of generalized hyperalgesia in mice with induced adenomyosis by levo-tetrahydropalmatine (l-THP) and andrographolide. Reprod Sci 2011; (In press).
13. Council NR. Guidefor the Care and Use of Laboratory Animals. Washington, DC: National Academies Press, 1996.
14. Bird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of the uterus: revisited. Am J Obstet Gynecol 1972; 112: 583-593.
15. Le Bars D, Gozariu M, Cadden SW. Animal models of noci-ception. Pharmacol Rev 2001; 53: 597-652.
16. Bannon AW, Malmberg AB. Models of nociception: hot-plate, tail-flick, and formalin tests in rodents. Curr Protoc Neurosci 2007; 41: 8.9.1-8.9.16.
17. Kooperberg C, Bose S, Stone CJ. Polychotomous regression. J Am Statist Assoc 1997; 92: 117-127.
18. Team RDC. R: A Language and Environmentfor Statistical Com-puting. Vienna: R Foundation for Statistical Computing, 2010.
19. Wu Y, Guo SW. Inhibition of proliferation of endome-trial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780. Gynecol Obstet Invest 2006; 62: 193-205. (Pubitemid 44763186)
20. Nebbioso A, Manzo F, Miceli M et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep 2009; 10: 776-782.
21. Wang J, Mahmud SA, Bitterman PB, Huo Y, Slungaard A. Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothe-lial cells and monocytes. J Biol Chem 2007; 282: 28408-28418. (Pubitemid 47606006)
22. Dong XF, Song Q, Li LZ, Zhao CL, Wang LQ. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor. Neuro Endocrinol Lett 2007; 28: 775-780.
23. Liu X, Nie J, Guo SW. Elevated immunoreactivity to tissue factor and its association with dysmenorrhea severity and the amount of menses in adenomyosis. Hum Reprod 2011; 26: 337-345.
24. Kogan EA, Niziaeva NV, Demura TA, Ezhova LS, Unanian AL. [The morphological and immunohiochemical features of foci of adenomyosis: in its concurrence with endometrial adenocarcinoma]. Arkh Patol 2010; 72: 7-12.
25. Lindstrom TM, Mohan AR, Johnson MR, Bennett PR. Histone deacetylase inhibitors exert time-dependent effects on nuclear factor-kappaB but consistently suppress the expression of proinflammatory genes in human myometrial cells. Mol Phar-macol 2008; 74: 109-121. (Pubitemid 351877001)
26. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009; 10: 895-926.
27. Kissler S, Zangos S, Kohl J et al. Duration of dysmenorrhoea and extent of adenomyosis visualised by magnetic resonance imaging. Eur J Obstet Gynecol Reprod Biol 2008; 137: 204-209. (Pubitemid 351423450)
28. Parker JD, Leondires M, Sinaii N, Premkumar A, Nieman LK, Stratton P. Persistence of dysmenorrhea and nonmenstrual pain after optimal endometriosis surgery may indicate adenomyosis. Fertil Steril 2006; 86: 711-715. (Pubitemid 44316812)
29. He W, Liu X, Zhang Y, Guo SW. Generalized hyperalgesia in women with endometriosis and its resolution following a successful surgery. Reprod Sci 2010; 17: 1099-1111.
30. Basselin M, Chang L, Chen M, Bell JM, Rapoport SI. Chronic administration of valproic acid reduces brain NMDA signal-ing via arachidonic acid in unanesthetized rats. Neurochem Res 2008; 33: 2229-2240.
31. Gao YJ, Ji RR. c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxi-ous stimulation and tissue injury? Open Pain J 2009; 2: 11-17.
32. Ikeuchi M, Kolker SJ, Burnes LA, Walder RY, Sluka KA. Role of ASIC3 in the primary and secondary hyperalgesia pro-duced byjoint inflammation in mice. Pain 2008; 137: 662-669.
33. Bai G, Wei D, Zou S, Ren K, Dubner R. Inhibition of class II histone deacetylases in the spinal cord attenuates inflamma-tory hyperalgesia. Mol Pain 2010; 6: 51.
34. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf2001; 24: 969-978. (Pubitemid 33097097)
35. Malick A, Jakubowski M, Elmquist JK, Saper CB, Burstein R. A neurohistochemical blueprint for pain-induced loss of appetite. Proc Natl Acad Sci USA 2001; 98: 9930-9935. (Pubitemid 32769406)
36. Stevenson GW, Bilsky EJ, Negus SS. Targeting pain-suppressed behaviors in preclinical assays of pain and anal-gesia: effects of morphine on acetic acid-suppressed feeding in C57BL/6J mice. J Pain 2006; 7: 408-416. (Pubitemid 43794888)
37. Greaves P, White IN. Experimental adenomyosis. Best Pract Res Clin Obstet Gynaecol 2006; 20: 503-510. (Pubitemid 44688619)
38. Lipschutz A, Iglesias R, Panasevich VI, Salinas S. Pathological changes induced in the uterus of mice with the prolonged administration ofprogesterone and 19-nor-contraceptives. Br J Cancer 1967; 21: 160-165.
39. Mori T, Nagasawa H. Mechanisms of development of prolactin-induced adenomyosis in mice. Acta Anat (Basel) 1983; 116: 46-54. (Pubitemid 13115351)
40. Mori T, Nagasawa H, Takahashi S. The induction of adenomyosis in mice by intrauterine pituitary isografts. Life Sci 1981; 29: 1277-1282. (Pubitemid 12238649)
41. Mori T, Kyokuwa M, Nagasawa H. Animal model of uter-ine adenomyosis: induction of the lesion in rats by ectopic pituitary isografting. Lab Anim Sci 1998; 48: 64-68. (Pubitemid 128521100)
42. Vercellini P, Cortesi I, Crosignani PG. Progestins for symp-tomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997; 68: 393-401. (Pubitemid 27412901)
43. Giudice LC. Clinical practice. Endometriosis. N Engl J Med 2010; 362: 2389-2398.
44. Nie J, Liu X, Guo SW. Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its cor-relation with dysmenorrhea in adenomyosis. Am J Obstet Gynecol 2010; 202: 346 e1-346 e8.
45. Biscaldi E, Ferrero S, Remorgida V, Rollandi GA. Bowel endometriosis: CT-enteroclysis. Abdom Imaging 2007; 32: 441-450. (Pubitemid 47383873)
46. Wu Y, Guo SW. Suppression of IL-1beta-induced COX-2 expression by trichostatin A (TSA) in human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol 2007; 135: 88-93. (Pubitemid 350026147)
47. Wu Y, Starzinski-Powitz A, Guo SW. Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod Sci 2007; 14: 374-382. (Pubitemid 351168805)
48. Wu Y, Starzinski-Powitz A, Guo SW. Constitutive and tumor necrosis factor-alpha-stimulated activation of nuclear factor-kappaB in immortalized endometriotic cells and their sup-pression by trichostatin A. Gynecol Obstet Invest 2010; 70: 23-33.
49. Igarashi M, Yokota Y, Igarashi T, Igarashi S, Abe Y, Liang S. Novel transvaginal echo-guided injection treatment for adenomyosis, vaginal, and deep endometriosis, and ovarian endometriosis with a danazol, 3-ethyl pyridine, or valproic acid solution. The First Asian Conference on Endometriosis Shanghai 2010.